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Introduction
Bronchodilators are the mainstay of treatment for the management of chronic obstructive pulmonary disease (COPD). Inhaled long-acting muscarinic antagonists (LAMAs), considered first-line bronchodilators, are widely used for the treatment of COPD (GOLD, 2011) . Important features of an ideal LAMA for use in COPD include strong selectivity for muscarinic type 3 (M 3 ) receptors, long duration of action (preferably 24 h), fast onset of action and the ability to deliver clinically meaningful bronchodilation, with a reassuring safety profile (Vogelmeier and Banerji, 2011; Donohue, 2005; GOLD, 2011) . A long duration of action implies both prolonged efficacy (Tashkin, 2005) and a once-daily dosage regimen that has the potential to boost patient compliance (Breekveldt-Postma et al., 2007; Tamura and Ohta, 2007; Smith et al., 1996) . It has also been proposed that bronchodilators with a long duration of action offer a relatively consistent improvement in airway caliber over time, in contrast to the peaks and troughs that might arise with bronchodilators that are dosed twice daily (Beeh and Beier, 2010) . Tiotropium, the most widely used LAMA worldwide, has a 24-h duration of action, but has several limitations, including a slow onset of action and a relatively high incidence of anticholinergic adverse events such as dry mouth (Barr et al., 2006) . NVA237 is a novel once-daily dry powder formulation of the LAMA glycopyrronium bromide, in development for the treatment of COPD. It has a rapid onset and long duration of action (> 24 h), with an acceptable safety and tolerability profile (Verkindre et al., 2010; Vogelmeier et al., 2010; Fogarty et al., 2011 , D'Urzo et al., 2011 . A rapid onset of action is a desirable feature of bronchodilators; rapid relief from symptoms provides reassurance of effect and may help improve compliance with the medication (Breekveldt-Postma et al., 2007; Bourbeau and Bartlett, 2008) .
Slow receptor kinetics have been implicated in the once-daily action of tiotropium (Disse et al., 1993) . Previous studies have shown that tiotropium has a slow dissociation half-life (t 1/2 ) from the M 3 receptor, with t 1/2 values of 34.7 h (Disse et al., 1993) and 27 h This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on August 1, 2012 as DOI: 10.1124/jpet.112.194456 at ASPET Journals on April 4, 2017 jpet.aspetjournals.org Casarosa et al., 2009) . In contrast, NVA237 has been shown to have a dissociation t 1/2 of 6.1 h (Casarosa et al., 2009) . It has been suggested that long receptor residency time is responsible for the once-daily duration of action of tiotropium observed in the clinic (Disse et al., 1999) . This observation is supported by results from in vitro studies in guinea pig trachea and human bronchi (Takahashi et al., 1994; Barnes et al., 1995) , which employed a washout procedure. However, such wash-out studies are complicated by the phenomenon of 'tissue rebinding' and do not represent a true measure of receptor dissociation rate (Vauquelin and Charlton, 2010) . In addition, radioligand binding studies describing the very slow dissociation of tiotropium cannot be considered representative of the physiological setting, having been performed at non-physiological temperature in the absence of sodium ions (Disse et al., 1993; Casarosa et al., 2009 and Haddad et al., 1994) . It has been reported that increasing the ionic strength of the assay buffer (increases in Na + , Ca
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, K + , Mg 2+ and Cl -concentrations were tested) decreased the affinity of muscarinic antagonists for their receptors (Birdsall et al., 1979) . Evaluation of the kinetic parameters of NVA237 and tiotropium at M 3 receptors under physiological Na + concentration and temperature should therefore be more relevant.
Tiotropium has a relatively slow onset of action, taking up to 3 h to achieve maximal bronchodilation (Casaburi et al., 2000) . Recent studies with NVA237 have shown the potential for a faster onset of action (Overend et al., 2008; Verkindre et al., 2010; Kuna et al., 2007) . As mentioned before, tiotropium has been associated with dry mouth at therapeutic doses (Casaburi et al., 2002) and other anticholinergic adverse events at higher doses (Kesten et al., 2009) . Muscarinic antagonists are also reported to have a potential for cardiac adverse effects, particularly in patients with underlying cardiac disease (Singh et al., 2008; Singh and Furberg, 2011) .
This study aimed to determine more clinically relevant dissociation rates by characterizing the binding of long-acting M 3 receptor antagonists at the M 1-5 receptors at
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37˚C in a physiologically relevant buffer containing 138 mM NaCl. We also investigated whether differences in the kinetic rate constants of NVA237 and tiotropium could explain the potential differences in onset of action, the observed improved cardiovascular therapeutic index with NVA237 in preclinical animal models (Trifilieff et al., 2007) and a potentially improved therapeutic index in humans.
JPET Fast Forward. IC 50 values were converted to equilibrium binding constants (pK i ) using previously described methods (Dowling and Charlton, 2006) . The kinetic parameters of unlabeled antagonists were assessed using a competition kinetic binding assay (Dowling and Charlton, 2006; Sykes et al., 2009 
IC 50 values obtained from the inhibition curves were converted to K i values using the method of Cheng and Prusoff (1973) . Dissociation data were fitted to a one-phase exponential decay function and the t 1/2 value obtained was transformed into a K off rate using:
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Specific binding = maximal specific binding*(1-exp(-1*K obs *time))
Where:
Association and dissociation rates for unlabeled antagonists were calculated using the equations described by Motulsky and Mahan (1984) : 
Fixing the above parameters allowed the following to be calculated: In order to calculate the kinetic parameters (K on and K off ) of tiotropium and NVA237,
we have employed the equations of Motulsky and Mahan (1984) receptor was found to be considerably shorter than the t 1/2 seen under non-physiological conditions (Table 1) . Dissociation of NVA237 from the M 3 receptor was four times faster than that of tiotropium under physiological conditions (Table 1) , but their kinetic on-rates were almost identical ( Table 2 ). The higher K off value of NVA237, therefore, appears to be the critical factor in determining its lower affinity at the M 3 receptor relative to tiotropium. This is true not only for these clinically relevant LAMAs, but also the antagonist radioligand NMS which has been used to quantify these kinetic parameters. receptor, whereas the residency time of NVA237 would be similar in both species. Onset of Action. Kinetic parameters were used to simulate the onset of action of NVA237 and tiotropium at a concentration 30-fold greater than their K i (Table 1 and Fig. 3,   A) . Simulations using the kinetic rate constants predicted that tiotropium would take 4-5 times longer than NVA237 to equilibrate with the M 3 receptor (at equi-effective concentrations) (Fig. 3, A) . This was confirmed in the in vitro calcium assay where NVA237 demonstrated a more rapid onset of action (5-fold faster) based on its ability to inhibit a submaximal concentration of methacholine relative to tiotropium (Fig. 3, B) . The t 1/2 of inhibition by NVA237 was 6.1 ± 2.1 min (n = 3), while the t 1/2 of inhibition by tiotropium was 29.4 ± 4.2 min (n = 3). A similar profile was observed in the rat tracheal strip assay using a concentration of NVA237 3-fold higher than that of tiotropium chosen based on its approximate 3-fold higher dose in the clinic (Fig. 3, C) . The t 1/2 of inhibition of the bethanecol response by NVA237 was 9.8 ± 0.8 min, while the t 1/2 of inhibition by tiotropium was 24.6 ± 2.3 min. Table 3 . The pK i of tiotropium was 10.05 ± 0.03 for M 2 receptors and 10.37 ± 0.04 for M 3 receptors (selectivity ratio: 2), and that of NVA237 was 8.70 ± 0.04 for M 2 receptors and 9.59 ± 0.05 for M 3 receptors (selectivity ratio: 7.8). Thus, NVA237 displayed a greater M 3 versus M 2 selectivity than tiotropium (7.8 versus 2-fold).
M3 selectivity ratio.
Determination of the kinetic parameters of NVA237, and tiotropium at M 1-5 receptors. Using the equations described by Motulsky and Mahan (1984) and the kinetic receptors; however, depending upon the compounds affinity for the various receptor subtypes, only a defined proportion of muscarinic receptors are occupied following administration of a single dose. Fig. 4 , A and B, represents a simulation of this situation using a concentration of NVA237 and tiotropium 30-fold greater than K i for the muscarinic M 3
receptor. In this simulation, various levels and speeds of receptor occupancy at the five muscarinic receptor subtypes can be observed -NVA237 is fully dissociated from M 1-5 receptors in less than 4 h, while some proportion of tiotropium is still bound to M 4 and M 5
receptors. In addition, NVA237 shows a much greater kinetic selectivity for the M 3 receptor over M 2 , M 4 and M 5 receptors, compared with tiotropium in this situation (Fig. 4, C) . The kinetic selectivity ratios obtained from these simulations are summarized in Table 4 . 
Discussion
The rationale for using a buffer with a physiological sodium chloride concentration (138 mM, HBSS) is based on the observation that sodium ions can significantly reduce muscarinic antagonist affinity (Birdsall et al., 1979) . Results from the current study confirm this important finding. Further, whole-cell binding studies performed in HBSS demonstrate an almost identical affinity and kinetic off rate for [ Charlton, 2012). Pharmacokinetic (PK) studies suggest that the systemic exposure achieved following inhalation of tiotropium and NVA237 is unlikely to produce functionally relevant occupancy of muscarinic receptors over a full 24-hour period (Disse et al., 1999; Sechaud et al., 2012) . As a consequence, systemic PK profiles for these particular compounds do not help rationalize their 24-h duration of action in COPD patients.
Perhaps a more compelling argument to explain the long duration of these agents comes from studies examining drug rebinding (Vauquelin and Charlton, 2010) . These studies predict that the rate of free drug elimination from the effect compartment is a key factor influencing the duration of action of a drug. The complex geometry of micro-anatomic features, such as the neuromuscular junction, may restrict the free diffusion of drug molecules away from the local environment where the receptors are concentrated, meaning that freshly dissociated drug is more likely to 'rebind' to the same receptor and/or receptors nearby. The process of rebinding has been suggested to occur at a local tissue level even when drug concentrations in the bulk phase have already dropped to insignificant levels (Vauquelin and Charlton, 2010) and may explain how NVA237 and tiotropium maintain their 24-h duration of action in the lung, despite their relatively rapid kinetic off rates.
Simulations using kinetic rate constants predict that tiotropium will take 4-5 times longer to equilibrate with the M 3 receptor than NVA237. This was confirmed in the in vitro calcium assay, where the onset of action of NVA237 was 5-fold faster than tiotropium, and in the rat tracheal strip, where the onset of action for NVA237 was 3-fold faster than that of tiotropium. These data suggest that NVA237 may exhibit a more rapid clinical onset of action than tiotropium, as previously described (Verkindre et al., 2010) .
This study further demonstrates that NVA237 is kinetically more selective (9-fold) for has a shorter t 1/2 on the M 1 receptor compared with tiotropium. These differences between the two compounds could have important consequences in terms of adverse-event profile.
Receptor complexes involved in adverse effects should ideally be readily reversible such that occupancy of the target by its endogenous ligand is dictated by its ability to compete with the free drug molecules; NVA237 clearly has considerable advantage over tiotropium in this regard.
Evidence from preclinical studies suggests an improved in vivo therapeutic index with NVA237 compared with tiotropium. In a rabbit model, NVA237 20 μ g and tiotropium 3 μ g both inhibited methacholine-induced bronchoconstriction, but NVA237 had no effect on the cardiovascular response to methacholine, in contrast to tiotropium (Cooper et al., 2006a; Cooper et al., 2006b) . In Brown Norway rat pre-treated intratracheally with NVA237 or tiotropium, NVA237 showed an improved therapeutic index over tiotropium, particularly for cardiovascular side effects (Trifilieff et al., 2007) . This may be explained by the higher selectivity of NVA237 for M 3 over M 2 receptors, as demonstrated in the current study.
Blockade of M 2 receptors attenuates the negative feedback inhibition of acetylcholine production, potentially reducing the bronchodilation produced by muscarinic agents (Belmonte, 2005) . Besides the cholinergic nerve endings, M 2 receptors are situated in the heart where they are thought to modulate pacemaker activity (Abrams et al., 2006) . Thus, there is concern about the potential cardiac adverse effects that muscarinic antagonists may have in patients (Singh et al., 2008; Singh and Furberg, 2011) . are associated with the anticholinergic adverse events related to muscarinic antagonists, such as dry mouth, constipation and gastrointestinal disturbances. The competition binding data obtained in the current study suggest that NVA237 is marginally more selective for M 3 and M 1 receptors over M 2 receptors, while tiotropium does not appear to distinguish between these three receptor subtypes. This contrasts with previous studies performed under nonphysiological conditions, which suggest that both compounds were non-selective for all three muscarinic subtypes (Haddad et al., 1999; Haddad et al., 1994; Casarosa et al., 2009 ).
Furthermore, despite NVA237 having a 6-fold lower equilibrium affinity than tiotropium for the M 3 receptor, in clinical studies it is only dosed 3-fold higher (Verkindre et al., 2010) contradicting suggestions (Casarosa et al., 2009 ) that it is over-dosed relative to tiotropium to achieve its once-daily duration of action.
In conclusion, the results of this study cast doubt over the hypothesis that clinical duration of action of LAMAs is directly governed by receptor residency time and suggest that there are other factors contributing to the 24-h duration of action of these compounds.
Indeed, recent studies have demonstrated that NVA237 has a 24-h duration of action, despite displaying a shorter receptor residency time than tiotropium (Verkindre et al., 2010; Vogelmeier and Banerji, 2011; Fogarty et al., 2011) . In addition, with its higher kinetic antagonists. The whole data set is summarized in Table 1 . Because the total binding varied from experiment to experiment, data are presented as the mean ± range from a representative of three or more experiments and plotted as specific bound. receptor under A, non-physiological and B, physiological conditions. The kinetic off rate (K off , k 2 ) of each ligand was fixed to those determined in the competition binding experiments, see Table 1 . The simulations in Fig. 2 represent receptor previously equilibrated with a saturating concentration of ligand. At t = 0, the concentration of free ligand is effectively reduced to zero and the ligand dissociates at a constant rate. at concentrations of 3 and 10 nM respectively, as used in the rat tracheal study. Data were simulated using the kinetic rate parameters stated in the text of the results section and equations detailed in the simulation section of the methods. 
